247 related articles for article (PubMed ID: 26581940)
1. Summaries of Safety Labeling Changes Approved By FDA-Boxed Warnings Highlights July-September 2015.
Am J Health Syst Pharm; 2015 Dec; 72(23):e60-8. PubMed ID: 26581940
[No Abstract] [Full Text] [Related]
2. Summaries of Safety Labeling Changes Approved By FDA--Boxed Warnings Highlights July--September 2015.
Am J Health Syst Pharm; 2015 Dec; 72(23):2008. PubMed ID: 26581924
[No Abstract] [Full Text] [Related]
3. Summaries of safety labeling changes approved by FDA-boxed warnings highlights January-March 2016.
Am J Health Syst Pharm; 2016 Jun; 73(11):e375-7. PubMed ID: 27208062
[No Abstract] [Full Text] [Related]
4. Summaries of safety labeling changes approved by FDA-Boxed Warnings Highlights October-December 2014.
Rubio T
Am J Health Syst Pharm; 2015 Mar; 72(5):343. PubMed ID: 25694404
[No Abstract] [Full Text] [Related]
5. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights October-December 2015.
Office of Health & Constituent Affairs U.S. Food and Drug Administration
Am J Health Syst Pharm; 2016 Mar; 73(5):267. PubMed ID: 26896495
[No Abstract] [Full Text] [Related]
6. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, January-March 2017.
Office of Health and Constituent Affairs, U.S. Food and Drug Administration
Am J Health Syst Pharm; 2017 Jun; 74(11):e292-e294. PubMed ID: 28546306
[No Abstract] [Full Text] [Related]
7. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, January-March 2019.
Am J Health Syst Pharm; 2019 Jun; 76(13):e8-e9. PubMed ID: 31361888
[No Abstract] [Full Text] [Related]
8. Summaries of safety labeling changes approved by FDA-boxed warnings highlights, January-March 2024.
Am J Health Syst Pharm; 2024 Jun; 81(13):e330-e334. PubMed ID: 38801728
[No Abstract] [Full Text] [Related]
9. Summaries of Safety Labeling Changes Approved By FDA-Boxed Warnings Highlights April-June 2015.
Am J Health Syst Pharm; 2015 Sep; 72(17):1430. PubMed ID: 26294231
[No Abstract] [Full Text] [Related]
10. Summaries of safety labeling changes approved by FDA-boxed warnings highlights January-March 2016.
Am J Health Syst Pharm; 2016 Jun; 73(11):739-40. PubMed ID: 27208054
[No Abstract] [Full Text] [Related]
11. Ethical and Practical Considerations in Removing Black Box Warnings from Drug Labels.
Yeh JS; Sarpatwari A; Kesselheim AS
Drug Saf; 2016 Aug; 39(8):709-14. PubMed ID: 27000800
[TBL] [Abstract][Full Text] [Related]
12. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, October-December 2019.
Am J Health Syst Pharm; 2020 Apr; 77(8):e6-e8. PubMed ID: 32236460
[No Abstract] [Full Text] [Related]
13. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, April-June 2018.
Office of Health and Constituent Affairs, U.S. Food and Drug Administration
Am J Health Syst Pharm; 2018 Sep; 75(17):e642-e653. PubMed ID: 30139737
[No Abstract] [Full Text] [Related]
14. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, July-September 2023.
Am J Health Syst Pharm; 2024 Jan; 81(2):3-4. PubMed ID: 37993264
[No Abstract] [Full Text] [Related]
15. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, July-September 2022.
Am J Health Syst Pharm; 2022 Dec; 79(24):e157-e160. PubMed ID: 36377403
[No Abstract] [Full Text] [Related]
16. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, July-September 2022.
Traynor K
Am J Health Syst Pharm; 2022 Dec; 79(24):2206-2207. PubMed ID: 36342044
[No Abstract] [Full Text] [Related]
17. Summaries of Safety Labeling Changes Approved By FDA—Boxed Warnings Highlights January-March 2015.
Rubio T
Am J Health Syst Pharm; 2015 Jun; 72(11):900, 902, 904. PubMed ID: 25987678
[No Abstract] [Full Text] [Related]
18. Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals.
Schick A; Miller KL; Lanthier M; Dal Pan G; Nardinelli C
Drug Saf; 2017 Jun; 40(6):497-503. PubMed ID: 28342075
[TBL] [Abstract][Full Text] [Related]
19. Impact of United States Food and Drug Administration's boxed warnings on adverse drug reactions reporting rates and risk mitigation for multiple myeloma drugs.
Garg V; Raisch DW; McKoy JM; Trifilio SM; Holbrook J; Edwards BJ; Belknap SM; Samaras AT; Nardone B; West DP
Expert Opin Drug Saf; 2013 May; 12(3):299-307. PubMed ID: 23480866
[TBL] [Abstract][Full Text] [Related]
20. Prescribing Antipsychotic Medications to Patients With Dementia: Boxed Warnings and Mitigation of Legal Liability.
Rose RV; Kass JS
Continuum (Minneap Minn); 2019 Feb; 25(1):254-259. PubMed ID: 30707196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
